Qualitative Evaluation of α-Synuclein: A Critical Step in Unravelling the Complexities of Autism Spectrum Disorder
- PMID: 36310016
- PMCID: PMC10267485
- DOI: 10.1159/000527728
Qualitative Evaluation of α-Synuclein: A Critical Step in Unravelling the Complexities of Autism Spectrum Disorder
Conflict of interest statement
Author Samuel Abraham is a shareholder in GN Corporation, Japan, which holds shares of Sophy Inc., Japan, the manufacturers of novel beta glucans using different strains of
Comment in
-
Reply to: "Qualitative Evaluation of α-Synuclein: A Critical Step in Unravelling the Complexities of Autism Spectrum Disorder".Med Princ Pract. 2023;32(1):98. doi: 10.1159/000528530. Epub 2023 Jan 10. Med Princ Pract. 2023. PMID: 36626877 Free PMC article. No abstract available.
Comment on
-
Plasma Levels of Alpha and Gamma Synucleins in Autism Spectrum Disorder: An Indicator of Severity.Med Princ Pract. 2021;30(2):160-167. doi: 10.1159/000513935. Epub 2020 Dec 21. Med Princ Pract. 2021. PMID: 33348337 Free PMC article.
References
-
- Tarakçıoğlu M, Cetin I, Özer Ö, Kaçar S, Çimen B, Kadak M. Low serum level α-synuclein and tau protein in autism spectrum disorder compared to controls. Neuropediatrics. 2015;46((6)):410–415. - PubMed
-
- Raghavan K, Dedeepiya VD, Ikewaki N, Sonoda T, Iwasaki M, Preethy S, et al. Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised parallel-group pilot clinical study. BMJ Neurol Open. 2022;4((1)):e000203. - PMC - PubMed